ES2091649T3 - Uso de rifaximina y composiciones farmaceuticas que la contienen en el tratamiento de la dispepsia gastrica causada por helicobacter pylori. - Google Patents

Uso de rifaximina y composiciones farmaceuticas que la contienen en el tratamiento de la dispepsia gastrica causada por helicobacter pylori.

Info

Publication number
ES2091649T3
ES2091649T3 ES94104308T ES94104308T ES2091649T3 ES 2091649 T3 ES2091649 T3 ES 2091649T3 ES 94104308 T ES94104308 T ES 94104308T ES 94104308 T ES94104308 T ES 94104308T ES 2091649 T3 ES2091649 T3 ES 2091649T3
Authority
ES
Spain
Prior art keywords
contain
pharmaceutical compositions
treatment
rifaximine
helicobacter pylori
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94104308T
Other languages
English (en)
Inventor
Antonella Ferrieri
Leone Gabriele Rotini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Application granted granted Critical
Publication of ES2091649T3 publication Critical patent/ES2091649T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DEL ANTIBIOTICO DE RIFAMICINA CONOCIDO POR EL NOMBRE DE RAFAXIMIN (INN) Y A LAS COMPOSICIONES FARMACEUTICAS QUE LO CONTIENEN EN EL TRATAMIENTO ORAL DE LAS FORMAS DE DISPEPSIA GASTRICA PROVOCADAS POR LA BACTERIA CONOCIDA "HELICOBACTER PYLORI". EL RIFAXIMIN PUEDE ADMINISTRARSE EN CUALQUIER FORMA FARMACEUTICA ORAL, PARTICULARMENTE TABLETAS, CAPSULAS, TABLETAS RECUBIERTAS DE AZUCAR, GRANULOS Y JARABES QUE CONTENGAN ENTRE 200 Y 2000 MILIGRAMOS DE PRINCIPIO ACTIVO, EN DOSIS DIARIAS DE ENTRE 400 Y 2000 MILIGRAMOS.
ES94104308T 1993-03-23 1994-03-18 Uso de rifaximina y composiciones farmaceuticas que la contienen en el tratamiento de la dispepsia gastrica causada por helicobacter pylori. Expired - Lifetime ES2091649T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93BO000099A IT1264494B1 (it) 1993-03-23 1993-03-23 Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Publications (1)

Publication Number Publication Date
ES2091649T3 true ES2091649T3 (es) 1996-11-01

Family

ID=11338806

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94104308T Expired - Lifetime ES2091649T3 (es) 1993-03-23 1994-03-18 Uso de rifaximina y composiciones farmaceuticas que la contienen en el tratamiento de la dispepsia gastrica causada por helicobacter pylori.

Country Status (11)

Country Link
US (1) US5352679A (es)
EP (1) EP0616808B1 (es)
JP (1) JP2755550B2 (es)
KR (1) KR0177846B1 (es)
AT (1) ATE142495T1 (es)
CA (1) CA2115381C (es)
DE (1) DE69400493T2 (es)
DK (1) DK0616808T3 (es)
ES (1) ES2091649T3 (es)
GR (1) GR3020984T3 (es)
IT (1) IT1264494B1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
AU5019196A (en) * 1995-02-07 1996-08-27 Narayan Krishnarao Athanikar Concomitant treatment with oral bismuth compounds
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
EP0861660B9 (en) * 1997-02-28 2006-06-28 Kaneka Corporation Curative medicine for disease caused by infection of Helicobacter
JP2005510534A (ja) * 2001-11-21 2005-04-21 アクティブバイオティクス インコーポレイティッド 標的化治療薬およびその使用
WO2003051299A2 (en) * 2001-12-13 2003-06-26 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
EP2420226B1 (en) † 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
DK2327407T3 (da) 2008-09-26 2014-08-25 Aska Pharm Co Ltd Profylaktisk og/eller terapeutisk middel til funktionelle gastrointestinale sygdomme
US20110035232A1 (en) * 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
SMT202400116T1 (it) 2008-10-02 2024-05-14 Salix Pharmaceuticals Ltd Trattamento dell’encefalopatia epatica utilizzando rifaximina
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
WO2010044093A1 (en) * 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
RU2012126084A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
US20130202654A1 (en) 2009-11-23 2013-08-08 Cipla Limited Topical Foam Composition
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
PT3546464T (pt) 2014-05-12 2020-08-05 Alfasigma Spa Preparação e utilização da forma cristalina tau de rifaximina solvatada com degme
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
EP3525825B1 (en) 2016-10-14 2024-03-20 Cipla Limited Pharmaceutical compositions comprising rifaximin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica

Also Published As

Publication number Publication date
ITBO930099A0 (it) 1993-03-23
GR3020984T3 (en) 1996-12-31
ATE142495T1 (de) 1996-09-15
KR0177846B1 (ko) 1999-03-20
DK0616808T3 (da) 1996-09-30
CA2115381C (en) 1999-01-05
ITBO930099A1 (it) 1994-09-23
DE69400493D1 (de) 1996-10-17
EP0616808B1 (en) 1996-09-11
JP2755550B2 (ja) 1998-05-20
IT1264494B1 (it) 1996-09-24
CA2115381A1 (en) 1994-09-24
JPH06298768A (ja) 1994-10-25
DE69400493T2 (de) 1997-01-23
EP0616808A1 (en) 1994-09-28
US5352679A (en) 1994-10-04

Similar Documents

Publication Publication Date Title
DK0616808T3 (da) Anvendelse af rifaximin og farmeaceutiske præparater indeholdende rifaximin til behandling af gastri sk dyspepsi forårsaget af Heliobacter pylori
GT199900203A (es) Composiciones de celecoxib.
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
AR019031A1 (es) Forma farmaceutica de dosificacion de efavirenz en capsula o tableta comprimida y metodo para su preparacion
ES2081531T3 (es) Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
ITRM930591A0 (it) Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
TNSN04095A1 (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
PE20050728A1 (es) Forma de dosificacion a prueba de abuso
AR024966A1 (es) Formulacion farmaceutica
AR042977A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
ATE311227T1 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
AR004510A1 (es) Composiciones que comprenden amoxicilina y clavulanato, procedimientos para su preparacion y el uso de las composiciones para la fabricacion de unmedicamento
ES2179832T3 (es) Formas de administracion orales con contenido en flupirtina solida, con liberacion controlada del principio activo.
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
ATE101594T1 (de) Einen zink-komplex enthaltende arzneimittel.
DE69927584D1 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
DE60025503D1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
BR0013106A (pt) Composição farmacêutica flutuante, comprimido, e processo de prepapação de um comprimido.
AR011457A1 (es) Sales de bismuto de antibioticos del grupo de la moenomicina, procedimiento para su preparacion, su utilizacion y medicamentos que contienen tales sales
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
ECSP003685A (es) Formulaciones orales de liberacion controlada
MY141008A (en) Oral formulations of deoxypeganine and their uses
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 616808

Country of ref document: ES